Entera Bio

Entera Bio Diluted EPS

The Diluted Earnings per Share of Entera Bio (ENTX) as of Oct 8, 2026 is -0.25 USD. In the previous year, Diluted Earnings per Share was -0.25 USD — a change of -2.28% (higher).

Diluted EPS

-0.25USD

YoY

-2.28%

Last updated:

Diluted Earnings per Share of Entera Bio is 2025 -0.25 USD. Diluted Earnings per Share of Entera Bio was 2024 -0.25 USD. It decreases by -2.28% higher compared to the previous year.

The Entera Bio Diluted EPS history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Diluted EPS
Date
Diluted EPS
Jan 1, 2018
-0.88 USD
Jan 1, 2019
-0.90 USD
Jan 1, 2020
-0.54 USD
Jan 1, 2021
-0.42 USD
Jan 1, 2022
-0.45 USD
Jan 1, 2023
-0.30 USD
Jan 1, 2024
-0.25 USD
Jan 1, 2025
-0.25 USD
The Entera Bio Diluted EPS history
YEARDiluted EPSYoY
-0.25USD-2.28%
-0.25USD-15.31%
-0.30USD-34.04%
-0.45USD+6.77%
-0.42USD-21.98%
-0.54USD-39.23%
-0.90USD+2.14%
-0.88USD-6.76%
-0.94USD+572.96%
-0.14USD+64.77%
-0.08USD—
Access this data via the Eulerpool API
Get Free API Key

Entera Bio Stock analysis

What does Entera Bio do? Entera Bio Ltd is an emerging biotechnology company focused on developing oral medications to treat unmet medical needs. The company was founded in 2010 and is headquartered in Jerusalem, Israel. Its history began with the discovery of the "EnteraGam" molecule in the intestinal cells of breastfed infants, which helps them fight infections. This led to the development of EnteraGam for the treatment of various autoimmune diseases. The company's business model is based on developing oral formulations for existing drugs and discovering and developing new molecules. Its focus areas are osteoporosis, hypoparathyroidism, chronic kidney disease, and autoimmune diseases. Entera Bio is divided into three business divisions: the Oral Protein Delivery Platform, the Oral Parathyroid Hormone (PTH) Platform, and the Collagen-based Platform for Wound Healing. Its products include EB611, a candidate for hypoparathyroidism treatment, EB613 for osteoporosis treatment, and EB612 for chronic kidney disease. These products have potential to improve the lives of millions of patients worldwide. Entera Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Entera Bio stock

Diluted Earnings per Share of Entera Bio is -0.25 USD in 2025.

Diluted Earnings per Share of Entera Bio changed from -0.25 USD to -0.25 USD, representing a -2.28% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Diluted Earnings per Share Entera Bio since 2006 – with annual values, charts, and detailed analysis.

Diluted EPS accounts for all potential shares from options, warrants, and convertible securities. It provides a more conservative per-share earnings measure.

Access this data via the Eulerpool API
Get Free API Key

Income Statement — Entera Bio

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Entera Bio